|
Rescinnamine
drug data and news
Rescinnamine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Rescinnamine
|
| Brand Names/Synonyms |
Anapral; Anaprel; Apolon; Apoterin; Apoterin S; Cartric; Cinamine; Cinatabs; Cinnaloid; Cinnasil; Methyl Trimethoxycinnamoylreserpate; Moderil; Normorescina; Paresinan; RESCINNAMINE; Raupyrol; Raurescin; Raurescine; Recinnamine; Recitensina; Rescaloid; Rescamin; Rescidan; Rescin; Rescinnamin; Rescinpal; Rescisan; Rescitens; Resealoid; Reserpinene; Reserpinin; Reserpinine; Resipal; Reskinnamin; Rozex; Scinnamina; Tenamine; Trimethoxycinnamoyl Methyl Reserpate; Tsuruselpi S; Tuareg |
| Indication |
For the treatment of hypertension |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
Used to treat hypertension. Rescinnamine inhibits angiotensin-converting enzyme. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. |
| Mechanism Of Action |
Binds to and inhibits the angiotensin converting enzyme. Rescinnamine competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. |
Rescinnamine News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
Not Available |
| Drug_Category |
Antihypertensive Agents; ATC:C02AA01 |
| Absorption |
Not Available |
| Interactions |
Not Available |
| Toxicity |
Not Available |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
Not Available |
| Chemical Formula |
C35H42N2O9 |
| Molecular Weight |
634.716 g/mol |
| Smiles String |
COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C=CC6=CC(=C(C(=C6)OC)OC)OC |
| Melting Point |
238.5 °C |
| Water Solubility |
Not Available |
| State |
Solid |
| LogP/Hphobicity |
3.85 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Not Available |
| Half Life |
Not Available |
| Protein Binding [%] |
Not Available |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
Not Available |
| Drug Type |
Approved Drug |
| Accession No |
APRD00112 |
| CAS Registry Number |
24815-24-5 |
| KEGG Compound ID |
C06540 |
| PubChem ID |
SID:8770 |
| PharmGKB ID |
PA451235 |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
Not Available
|
|
|
